Full Text
EE229 Cost-Effectiveness Analysis of First-Line Tremelimumab Plus Durvalumab Versus Sorafenib in Unresectable Hepatocellular Carcinoma

Abstract

Authors

CHI-HAN CHENG Xiao Zang Wendy St. Peter

Back to Volume 28, Supplemental Issue 6S1
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×